CaSfA - Cancer Support for All
News from CaSfA's Director

January 2015

New Finding in Triple Negative Breast Cancer

Researchers in the UK have found an overactive gene, BCL11A, in 8 out of 10 patients with triple-negative breast cancer.  This type of cancer is especially aggressive. Without estrogen, progesterone and HER2 receptors targeted therapy using tamoxifen, aromatase inhibitors, and Herceptin do not work.  Finding this gene is the first step in developing targeted therapy for this type of breast cancer.  ( )
Website Builder provided by  Vistaprint